Original Query: ALL
Previous Study | Return to List | Next Study

Effects of H1-Antagonist on Cognition

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00846950
Recruitment Status : Completed
First Posted : February 19, 2009
Last Update Posted : February 19, 2009
Information provided by:
Maastricht University Medical Center

Brief Summary:
The purpose of this study is to determine whether histamine is involved in memory and specific processes in human cognition.

Condition or disease Intervention/treatment
Cognition Drug: dexchlorpheniramine, lorazepam

Detailed Description:
The neurotransmitter histamine appears to be involved in human cognitive performance. However, the exact role is very unclear. The role it plays in memory performance is highly disputed, as animal studies show decreased performance when the H1-receptor is blocked in the central nervous system while such findings in humans is scarce. To clarify the role of histamine in human memory and different processes in cognition, the effects of an H1-antagonist (dexchlorpheniramine) on memory, alertness and sensory and motor processes are measured. The study will be conducted according to a within subject cross-over design using healthy volunteers.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Official Title: Effects of H1-Antagonist on Stages of Human Information Processing
Study Start Date : December 2006
Primary Completion Date : May 2007
Study Completion Date : May 2007

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Arm Intervention/treatment
Experimental: healthy volunteers Drug: dexchlorpheniramine, lorazepam

Primary Outcome Measures :
  1. P300 latency and LRP onset latency [ Time Frame: 1.5 hours after treatment ]

Secondary Outcome Measures :
  1. Words recalled [ Time Frame: 1.5 hours after treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy as determined by a physician

Exclusion Criteria:

  • present or history of any neurological of psychiatric disease
  • present or history of any substance abuse

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00846950

Faculty of Psychology and Neuroscience, Maastricht University
Maastricht, Limburg, Netherlands, 6229 ER
Sponsors and Collaborators
Maastricht University Medical Center
Principal Investigator: Annemiek Vermeeren, Ph.D. Maastricht University hospital

Additional Information:
Responsible Party: Effects of H1-antagonist on stages of human information processing, Dr. A. Vermeeren Identifier: NCT00846950     History of Changes
Other Study ID Numbers: 06-3-075
First Posted: February 19, 2009    Key Record Dates
Last Update Posted: February 19, 2009
Last Verified: February 2009

Keywords provided by Maastricht University Medical Center:
Event Related Potentials
Information processing
The effects of an H1 antagonist (dexchlorpheniramine) on human cognition

Additional relevant MeSH terms:
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Gastrointestinal Agents
Hypnotics and Sedatives
Central Nervous System Depressants
Anti-Anxiety Agents
Tranquilizing Agents
Psychotropic Drugs
GABA Modulators
GABA Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents
Dermatologic Agents
Anti-Allergic Agents